Implant Sciences Corporation (AMEX: IMX), a high technology
supplier of sophisticated systems and sensors for the homeland security
market and related industries, today announced it has received its first
order purchased through its recently awarded General Services
Administration (GSA) Schedule Contract. The order, from a component of
the Department of Defense, is for two (2) of the Company's Quantum
Sniffer™ QS-H150 Portable Explosives
Detectors.
"Receiving our first order from the GSA
schedule less than two weeks after contract award is a rewarding
culmination of our team’s efforts. We are
enthusiastic about the additional sales opportunities that the GSA
contract award has made possible from a wide range of federal, state,
and local government agencies and their affiliates,”
said Richard Meyerhoff, VP of Worldwide Sales and Service for Implant
Sciences Corp.
The QS-H150 provides high performance and reliability combined with a
very low comparative cost of ownership. Annual maintenance costs are
minimal and consist primarily of normal care and cleaning using common,
low cost supplies. Calibration is autonomous, continuous, and requires
no consumables. Since there are no radioactive materials used in the
QS-H150, there are no associated certifications, licenses, inspections,
or end-of-life disposal issues for users to contend with. As such,
customers have an outstanding, cost effective product available to them
in support of efforts to improve their overall security profile and meet
mission critical objectives.
About Implant Sciences
Implant Sciences develops, manufactures and sells sophisticated sensors
and systems for the Security, Safety and Defense (SS&D) industries. The
Company has developed proprietary technologies used in its commercial
portable and bench-top explosive trace detection systems which ship to a
growing number of locations domestically and internationally. For
further details on the Company and its products, please visit the Company’s
website at www.implantsciences.com.
Safe Harbor Statement
This press release contains certain "forward-looking
statements,” as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such statements are
based on management’s current expectations
and are subject to risks and uncertainties that could cause the Company’s
actual results to differ materially from the forward-looking statements.
Such risks and uncertainties include, but are not limited to, the Company’s
ability to successfully sell its QS-H150 products to government agencies
authorized to procure goods and services from the GSA schedule, the
inability of the Company to expand and strengthen its governmental
distribution channel, the risk that the Company will not realize the
anticipated benefits of the GSA schedule, and other risks and
uncertainties described in the Company’s
filings with the Securities and Exchange Commission, including its most
recent Forms 10-K, 10-Q and 8-K.
For further information, you are encouraged to review Implant Sciences’
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the period ended June 30, 2007 and
Quarterly Reports for the periods ended September 30, 2007, December 31,
2007 and March 31, 2008. The Company assumes no obligation to update the
information contained in this press release.
